Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

BIOMARKER:

NRAS Q61R

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

Related biomarkers:

‹

›

NRAS Q61R	Hepatocellular Cancer	NRAS Q61R	Hepatocellular Cancer	sorafenib + BAY86-9766 Sensitive: C3 – Early Trials sorafenib + BAY86-9766 Sensitive : C3	sorafenib + BAY86-9766 Sensitive: C3 – Early Trials sorafenib + BAY86-9766 Sensitive : C3
NRAS Q61R	Melanoma	NRAS Q61R	Melanoma	vemurafenib Resistant: C3 – Early Trials vemurafenib Resistant : C3	vemurafenib Resistant: C3 – Early Trials vemurafenib Resistant : C3
NRAS Q61R	Melanoma	NRAS Q61R	Melanoma	tunlametinib Sensitive: C3 – Early Trials tunlametinib Sensitive : C3	tunlametinib Sensitive: C3 – Early Trials tunlametinib Sensitive : C3
NRAS Q61R	Thyroid Gland Carcinoma	NRAS Q61R	Thyroid Gland Carcinoma	selumetinib Sensitive: C3 – Early Trials selumetinib Sensitive : C3	selumetinib Sensitive: C3 – Early Trials selumetinib Sensitive : C3
NRAS Q61R	Melanoma	NRAS Q61R	Melanoma	trametinib + dabrafenib Sensitive: C3 – Early Trials trametinib + dabrafenib Sensitive : C3	trametinib + dabrafenib Sensitive: C3 – Early Trials trametinib + dabrafenib Sensitive : C3
NRAS Q61R	Melanoma	NRAS Q61R	Melanoma	nivolumab + ipilimumab Sensitive: C4 – Case Studies nivolumab + ipilimumab Sensitive : C4	nivolumab + ipilimumab Sensitive: C4 – Case Studies nivolumab + ipilimumab Sensitive : C4
NRAS Q61R	Melanoma	NRAS Q61R	Melanoma	mirdametinib Sensitive: D – Preclinical mirdametinib Sensitive : D	mirdametinib Sensitive: D – Preclinical mirdametinib Sensitive : D
NRAS Q61R	Thyroid Gland Anaplastic Carcinoma	NRAS Q61R	Thyroid Gland Anaplastic Carcinoma	MK-2206 Sensitive: D – Preclinical MK-2206 Sensitive : D	MK-2206 Sensitive: D – Preclinical MK-2206 Sensitive : D
NRAS Q61R	Melanoma	NRAS Q61R	Melanoma	PHI-501 Sensitive: D – Preclinical PHI-501 Sensitive : D	PHI-501 Sensitive: D – Preclinical PHI-501 Sensitive : D